Candriam S.C.A. Decreases Holdings in Biogen Inc. $BIIB

Candriam S.C.A. lowered its stake in Biogen Inc. (NASDAQ:BIIB) by 2.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 158,821 shares of the biotechnology company’s stock after selling 4,494 shares during the period. Candriam S.C.A. owned approximately 0.11% of Biogen worth $22,248,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in BIIB. Empowered Funds LLC lifted its position in Biogen by 64.9% in the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after purchasing an additional 2,777 shares during the period. Focus Partners Wealth boosted its stake in shares of Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after buying an additional 6,436 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in Biogen during the second quarter worth $216,000. Blair William & Co. IL raised its position in Biogen by 11.8% in the second quarter. Blair William & Co. IL now owns 14,844 shares of the biotechnology company’s stock worth $1,864,000 after acquiring an additional 1,561 shares in the last quarter. Finally, Callan Family Office LLC acquired a new stake in Biogen in the second quarter valued at $308,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $193.81 on Tuesday. The company has a 50-day simple moving average of $177.26 and a 200-day simple moving average of $157.48. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The company has a market cap of $28.43 billion, a PE ratio of 22.00, a price-to-earnings-growth ratio of 1.70 and a beta of 0.16. Biogen Inc. has a 12 month low of $110.04 and a 12 month high of $202.41.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business’s revenue was down 7.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on BIIB. Wall Street Zen lowered shares of Biogen from a “buy” rating to a “hold” rating in a research report on Sunday, November 9th. Wolfe Research set a $231.00 price objective on Biogen in a research note on Monday. Morgan Stanley set a $190.00 price objective on Biogen in a report on Sunday. Mizuho upped their target price on Biogen from $177.00 to $207.00 and gave the company an “outperform” rating in a report on Thursday, January 8th. Finally, UBS Group began coverage on Biogen in a research note on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price target for the company. Thirteen investment analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat.com, Biogen has a consensus rating of “Hold” and an average target price of $206.21.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance: Biogen reported fourth‑quarter and FY results ahead of expectations, prompting analysts to raise forecasts and price targets — a direct earnings-driven positive catalyst. Biogen Posts Q4 Beat, Analysts Raise Price Targets
• Positive Sentiment: Regulatory progress for Leqembi: A biologics license application for a subcutaneous formulation of Leqembi was designated for priority review — this could expand prescribing convenience and bolster long‑term franchise value. Biologics License Application for Subcutaneous LEQEMBI Designated for Priority Review
• Positive Sentiment: Geographic expansion: Reports that China fast‑tracked at‑home use of Leqembi add another potential growth market for the Alzheimer’s franchise. Biogen stock to pop again? China fast-tracks Leqembi
• Positive Sentiment: Big analyst upgrades: RBC raised its price target to $233 (Outperform) and HC Wainwright raised its target to $228 (Buy), both signalling double‑digit upside from current levels and reflecting confidence in Leqembi and cash‑flow prospects. RBC Raises Price Target on Biogen to $233
• Neutral Sentiment: Mixed/neutral analyst stances: Several shops (Citigroup, Piper Sandler, Wedbush, Truist) nudged price targets higher but kept Neutral/Hold ratings, leaving investor guidance mixed. Analyst Price Target Moves (Citigroup, Piper, Wedbush, Truist)
• Negative Sentiment: Franchise pressure and execution risk: Analysis points to MS‑franchise weakness and near‑term growth limits, which keep some analysts cautious despite the Alzheimer’s upside. Biogen FY25 Earnings: Stable EPS Amid MS Franchise Pressure

Insider Buying and Selling

In related news, insider Priya Singhal sold 748 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $179.30, for a total transaction of $134,116.40. Following the completion of the transaction, the insider owned 6,271 shares of the company’s stock, valued at approximately $1,124,390.30. This represents a 10.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.18% of the company’s stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.